Paolo Cavazza
Geen lopende functies
Vermogen: 11 M $ op 30-04-2024
Profiel
Paolo Cavazza worked as a Principal at SciClone Pharmaceuticals LLC.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 30-06-2023 | 76 580 898 ( 13.01% ) | 11 M $ | 30-04-2024 |
Eerdere bekende functies van Paolo Cavazza
| Bedrijven | Functie | Einde |
|---|---|---|
| SCICLONE PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 1 |
|---|---|
SciClone Pharmaceuticals LLC
 SciClone Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology SciClone Pharmaceuticals LLC was engaged in the development of therapeutic treatment for oncology, infectious diseases, and cardiovascular disorders. It was also offering ZADAXIN for the treatment of hepatitis B, hepatitis C, certain cancers, and used as immune system enhancer, and DC Bead which is used for the novel treatment of liver cancer. The company was founded in 1990 and was headquartered in San Mateo, CA. | Health Technology |
